http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021089845-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9ca0632596f3342a71f604d9152b9e1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2020-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4814a44e384036fa111ad5a931159924 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5480b1968fb1c0873f72de8caeb4e075 |
| publicationDate | 2021-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021089845-A1 |
| titleOfInvention | Cd93 inhibitors for use in the treatment of cancer |
| abstract | The present invention relates to compounds of formula (1): Ar-L-N(R1)(R2), for use in the treatment of cancer. The compounds of formula (1) are characterized by a mono-, bi- or tricyclic aryl or heteroaryl (Ar) and a basic nitrogen atom with R1 and R2 being a linear alkyl or forming an aliphatic or heterocyclic ring. The aryl or heteroaryl and the basic nitrogen atom are connected via a linker L. The compounds of formula (1) are potent inhibitors of CD93, particularly of the CD93 intracellular domain. |
| priorityDate | 2019-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.